Comparative Pharmacology
Head-to-head clinical analysis: DIHYDROERGOTAMINE MESYLATE versus HYDROGENATED ERGOT ALKALOIDS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIHYDROERGOTAMINE MESYLATE versus HYDROGENATED ERGOT ALKALOIDS.
DIHYDROERGOTAMINE MESYLATE vs HYDROGENATED ERGOT ALKALOIDS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dihydroergotamine mesylate is an ergot alkaloid with potent agonist activity at serotonin 5-HT1B/1D receptors, leading to vasoconstriction of cranial blood vessels. It also has partial agonist/antagonist activity at alpha-adrenergic and dopamine receptors, contributing to its antimigraine effects.
Hydrogenated ergot alkaloids act as partial agonists/antagonists at α-adrenergic receptors, serotonergic (5-HT1B/1D) receptors, and dopaminergic receptors. They cause vasoconstriction by activating α-adrenoceptors and 5-HT receptors on vascular smooth muscle, and inhibit prolactin secretion via D2 receptor agonism.
1 mg intramuscularly or subcutaneously, repeat at 1-hour intervals as needed, maximum 3 mg per 24 hours and 6 mg per week; intravenous use is reserved for severe cases: 0.5-1 mg IV, may repeat once after 1 hour, maximum 2 mg per 24 hours.
1 mg orally three times daily, or 0.3 mg intramuscularly or subcutaneously once daily.
None Documented
None Documented
Terminal half-life is approximately 9 hours (range 7-13 hours) after IM administration; clinical effect duration corresponds to this elimination phase.
2-3 hours for dihydroergotamine; 12-15 hours for ergoloid mesylates, requiring cautious dosing in hepatic impairment.
Primarily hepatic metabolism; <10% excreted unchanged in urine; biliary/fecal excretion accounts for ~90% of metabolites.
Primarily hepatic metabolism (70-80%) with biliary excretion; renal excretion accounts for less than 10% of unchanged drug.
Category D/X
Category C
Ergot Alkaloid
Ergot Alkaloid